14 August 2025
14 August 2025
Eli Lilly said it will vigorously defend the allegations brought by the state of Texas.
Basilea expects to begin a Phase III trial with the antibiotic candidate in around 18 months.
The deals were signed with Galibra Neuroscience and Emugen Therapeutics, alongside a biotech company.
Our editorial team dives into the pharma industry's reaction to US tariffs on imports from the European Union and major trends from Q2 earnings calls.
The ketamine product is the first to be approved in an analgesic setting by the US regulator.
Brinsupri becomes the first bronchiectasis therapy while ushering in a new class of DPP1 inhibitors.
South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.
Basilea expects to begin a Phase III trial with the antibiotic candidate in around 18 months.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
